You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

NORVIUM BIOSCIENCE Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for NORVIUM BIOSCIENCE, and when can generic versions of NORVIUM BIOSCIENCE drugs launch?

NORVIUM BIOSCIENCE has two hundred and forty-seven approved drugs.

There are four US patents protecting NORVIUM BIOSCIENCE drugs. There is one tentative approval on NORVIUM BIOSCIENCE drugs.

There are fifty-one patent family members on NORVIUM BIOSCIENCE drugs in twenty-one countries and five hundred and forty-one supplementary protection certificates in seventeen countries.

Summary for NORVIUM BIOSCIENCE
International Patents:51
US Patents:4
Tradenames:197
Ingredients:185
NDAs:247

Drugs and US Patents for NORVIUM BIOSCIENCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Norvium Bioscience GABAPENTIN gabapentin TABLET;ORAL 090335-001 Jun 1, 2010 DISCN No No ⤷  Subscribe ⤷  Subscribe
Norvium Bioscience RANITIDINE HYDROCHLORIDE ranitidine hydrochloride CAPSULE;ORAL 075564-002 Oct 27, 2000 DISCN No No ⤷  Subscribe ⤷  Subscribe
Norvium Bioscience NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074367-002 Aug 31, 1994 DISCN No No ⤷  Subscribe ⤷  Subscribe
Norvium Bioscience TERAZOSIN HYDROCHLORIDE terazosin hydrochloride CAPSULE;ORAL 075140-002 Feb 11, 2000 DISCN No No ⤷  Subscribe ⤷  Subscribe
Norvium Bioscience ROPINIROLE HYDROCHLORIDE ropinirole hydrochloride TABLET;ORAL 078881-003 May 5, 2008 DISCN No No ⤷  Subscribe ⤷  Subscribe
Norvium Bioscience CLARITHROMYCIN clarithromycin TABLET;ORAL 065195-001 Mar 11, 2005 DISCN No No ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NORVIUM BIOSCIENCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Norvium Bioscience DEMADEX torsemide TABLET;ORAL 020136-002 Aug 23, 1993 RE30633 ⤷  Subscribe
Norvium Bioscience MIACALCIN calcitonin salmon SPRAY, METERED;NASAL 020313-002 Aug 17, 1995 5,759,565 ⤷  Subscribe
Norvium Bioscience LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 6,126,920 ⤷  Subscribe
Norvium Bioscience DEMADEX torsemide TABLET;ORAL 020136-003 Aug 23, 1993 4,822,807 ⤷  Subscribe
Norvium Bioscience ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019677-001 Nov 6, 1991 4,952,586 ⤷  Subscribe
Norvium Bioscience DEMADEX torsemide TABLET;ORAL 020136-001 Aug 23, 1993 RE30633 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for NORVIUM BIOSCIENCE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Foam 0.12% ➤ Subscribe 2007-08-10
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Inhalation Solution 0.021% and 0.042% ➤ Subscribe 2005-10-19
➤ Subscribe Foam 2% ➤ Subscribe 2009-07-30
➤ Subscribe Topical Foam 0.05% ➤ Subscribe 2005-06-27
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2006-12-13
➤ Subscribe Nasal Spray 0.125 mg base/spray ➤ Subscribe 2005-11-14

Supplementary Protection Certificates for NORVIUM BIOSCIENCE Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1663240 59/2015 Austria ⤷  Subscribe PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
2822954 SPC/GB18/031 United Kingdom ⤷  Subscribe PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625
0914118 PA2007001 Lithuania ⤷  Subscribe PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
1506211 C 2014 029 Romania ⤷  Subscribe PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116
1412357 77 5006-2008 Slovakia ⤷  Subscribe PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
1453521 132016000025143 Italy ⤷  Subscribe PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.